Frequency Therapeutics (FREQ) Peer Comparison

$0.30

$-13.84 (-97.88%)

As on 03-Nov-2023 16:00EDT

Market cap

$11 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Market cap ($ Mln)	11	120
Revenue ($ Mln)	--	--
Net Profit ($ Mln)	-59.32	-57.66
Net Margin (%)	--	-13,662.32
RoE (%)	-131.83	-40.80
Price to Earnings	--	--
Price-To-Book	0.91	0.28

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Operating Revenue	0.00	0.00
Cost of Revenue	--	--
Gross Profit	14.07	--
Operating Expenses	83.00	76.48
Operating Profit (EBIT)	-83.00	-76.48
Other Income	--	-0.07
Profit before Tax	-81.58	-73.89
Provision for Tax	0.00	-5.17
Profit after Tax (Net Income)	-81.58	-68.73
Minority Interest	--	--
Consolidated Profit	-84.69	-47.83

Liabilities ($ Mln)

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Shareholder's Funds	-261.67	180.06
Minority Interest	--	--
Non-Current Liabilities	31.02	2.20
Current Liabilities	21.03	11.46
Total Liabilities	121.24	193.72

Assets ($ Mln)

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Non-Current Assets	33.75	8.10
Current Assets	87.49	185.61
Total Assets	-209.62	193.72
Total Debt*	42.95	2.88
Net Current Assets	66.47	174.15

Cashflow ($ Mln)

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Cash From Operating Activities	-58.24	-60.86
Cash Flow from Investing Activities	-66.13	-96.39
Cash from Financing Activities	-0.58	0.24
Net Cash Inflow / Outflow	--	1.03

Ratios

Profitability Ratios

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
ROCE (%)	385.78	-32.29
ROE (%)	124.70	-32.51
ROA (%)	-53.22	-30.88
EBIT Margin (%)	--	--
Net Margin (%)	-601.98	74,090.77
Cash Profit Margin (%)	--	--

Growth Ratios

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Revenue Growth (%)	-1.00	--
EBIT Growth (%)	--	--
Net Profit Growth (%)	3.67	-42.71
EPS Growth (%)	0.05	-12.97
Book Value Growth (%)	--	--

Valuation Ratios

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Price / Earnings	-1.66	-0.06
Price / Book Value	-0.52	0.02
Dividend Yield (%)	--	--
EV/EBITDA	-0.80	2.34
Market Cap ($ Cr)	--	--

Solvency Ratios

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Debt to Equity	-0.16	0.02
Short term debt to equity ratio	-0.05	0.01
Current Ratio	4.16	16.19
Quick Ratio	3.99	--
Interest Coverage	-86.37	-29.61

Operating Efficiency Ratios

	Frequency Therapeutics (FREQ)	Talaris Therapeutics (TALS)
Debtors to sales (%)	1.02	--
Asset Turnover	0.00	0.00
Receivable days	6.28	--
Inventory Days	--	--
Payable days	--	--
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly